Esta página aún no está traducida al español y se muestra en inglés. Estamos trabajando en su traducción.

Exosome and small-molecule supply for hair and scalp protocols

ExaVeyra supplies exosome formats for topical aesthetic use to licensed practices, refers prescribers to a 503A compounding pharmacy that prepares hair and scalp formulations against an individual prescription where it holds a non-resident license, and publishes the literature and the FDA position on each formulation class so that a practice can read both before it applies for an account. This page is the door onto all of it: the blog series, the peer-reviewed science pages, the product category, and the supply pages by region and by state.

Written for licensed practitioners and practice operators: the literature, the formulation classes, and the sourcing position for each, with the regulatory notice beside every product.

Two product classes, each on its own pathway

What ExaVeyra supplies for a hair and scalp protocol, and under which regime
Product classShips toRegime
Exosome formats for topical aesthetic useEvery state and Puerto RicoTopical aesthetic use by licensed practitioners. Lot characterization and a certificate of analysis available on request. No exosome product is FDA-approved.
Compounded 503A formulationsWhere the 503A pharmacy partner holds a non-resident licensePrescription products prepared for one patient. Not FDA-approved finished drug products. Listed in the hair and scalp formulations category.

The evidence, one formulation class at a time

4 of 9 references published, with the study design labeled beside every citation.

Labeled medical illustration of a hair follicle in skin, showing the hair shaft, sebaceous gland, arrector pili muscle, hair bulb, matrix and papilla
Fig. 1 | Anatomy of the hair follicle, from shaft to dermal papilla.Imagen: BruceBlauscrédito

The Hair Follicle Cycle and the Levers a Protocol Acts On

In review

Finasteride: Mechanism, Approved Label, and Topical Literature

The oral label, the topical literature, and the FDA alert.

Minoxidil, Minoxidil Sulfate, and Follicular Sulfotransferase

The prodrug, the enzyme, and the combinations.

GHK-Cu in Follicle and Dermal Papilla Research

Follicle culture, animal models, and the regulatory position.

Extracellular Vesicles and Dermal Papilla Signaling

The human evidence to date, the registry, and the FDA communications.

Ketoconazole and Azelaic Acid in Scalp Research

In review

Vitamin D, Biotin, Thyroid and Sex Steroids in Hair Shedding

In review

Microneedling, PRP and Topical Anesthesia in Scalp Protocols

In review

FDA Communications Relevant to Hair Products

In review

Supply by region and by state

Each regional page answers what a practice in that place can source, how cold-chain material arrives, and where the state law questions are answered. Compounded availability on every page is read from the same registry as the coverage table, so the pages cannot disagree with each other.

Aspen, COAtlanta and Buckhead, GABoca Raton, FLCalabasas, CAChicago and the North Shore, ILCoral Gables, FLDallas and Highland Park, TXDenver and Cherry Hills, COFort Lauderdale, FLHouston and River Oaks, TXLas Vegas and Summerlin, NVMalibu, CAManhattan, NYMiami, FLMiami Beach, FLNaples, FLNewport Beach, CAPalm Beach and West Palm Beach, FLPhoenix, AZScottsdale, AZSeattle, WAAustin, TXBellevue and Medina, WABeverly Hills, CABoulder, COFort Worth and Southlake, TXThe Hamptons and Long Island, NYJacksonville and Ponte Vedra, FLSan Diego and La Jolla, CALos Angeles, CAPhiladelphia and the Main Line, PAOrlando and Winter Park, FLPalo Alto and Atherton, CASan Jose, CASanta Clara, CAMountain View, CAParadise Valley, AZPrinceton, NJReno and Lake Tahoe, Nevada, NVSan Antonio, TXSan Francisco and Marin, CASarasota, FLTampa, FLTucson, AZVail, COBeaver Creek and Avon, COSunny Isles Beach and Aventura, FLBrooklyn, NYWestchester, NYBig Sky and Bozeman, MTBoise, IDBloomfield Hills and Birmingham, MICleveland, OHIndianapolis and Carmel, INJackson Hole, WYMilwaukee, WINew Orleans, LAOklahoma City, OKOverland Park, KSSalt Lake City, UTSan Juan and Condado, PRSt. Louis and Ladue, MOWashington DC, DCPensacola and Gulf Breeze, FLLaguna Beach and Dana Point, CACarlsbad and Rancho Santa Fe, CACarmel and Pebble Beach, CAPalm Springs and Rancho Mirage, CASacramento, CASanta Barbara and Montecito, CASouth Lake Tahoe and Truckee, CABethesda and Chevy Chase, MDBirmingham and Mountain Brook, ALBoston and Wellesley, MACharleston, SCCharlotte, NCHonolulu, HIMinneapolis and Edina, MNPittsburgh, PAJupiter and Palm Beach Gardens, FLGreenwich, Westport and Fairfield County, CTNashville, TNPortland and Lake Oswego, ORRichmond, VAHuntington Beach, CA

States where compounded formulations ship today

Program questions

Are GHK-Cu or exosome products FDA-approved for hair loss or any form of alopecia?
Oral one-milligram finasteride and topical minoxidil are the two FDA-approved actives in this area. The FDA has approved no exosome product of any kind, and GHK-Cu is not approved for hair loss or any form of alopecia; compounded formulations that contain them are not FDA-approved finished drug products and are prepared under section 503A against an individual prescription. The evidence pages state the regulatory position for each formulation class beside its literature.
What does ExaVeyra supply for a hair and scalp protocol, and under which regime?
Two product classes, each on its own pathway. Exosome material for topical aesthetic use, characterized per lot with a certificate of analysis available on request, ships to licensed practices in every state and Puerto Rico. Compounded 503A preparations, the topical solutions, creams and oral capsules listed in the hair and scalp formulations category, are prepared to an individual prescription by the 503A pharmacy partner and dispensed by that pharmacy where it holds a non-resident pharmacy license; the coverage page and the regional pages state where that is.
Who is the program written for?
Licensed practitioners and practice operators. The blog series is written to be read; the science pages are written to be cited, with the study design labeled beside every reference; the regional and state pages answer what a practice in a given place can source and how it arrives. None of it is written for patients, and ExaVeyra takes no part in any diagnosis, treatment decision or plan of care.
Does ExaVeyra supply controlled substances?
No. Testosterone and the other anabolic agents that appear in the hormonal-context article are discussed there because the literature connects them to shedding, and the article says so; ExaVeyra Sciences does not supply controlled substances.

Créditos de imágenes

  1. Fig. 1BruceBlaus (Blausen.com staff, 2014, Medical gallery of Blausen Medical 2014, WikiJournal of Medicine 1(2), doi:10.15347/wjm/2014.010), Wikimedia Commons, CC BY 3.0. ↩

Nothing on this page has been reviewed or approved by the FDA. There are no FDA-approved exosome products. Exosome material distributed by ExaVeyra Sciences is supplied for topical aesthetic use by licensed practitioners, consistent with the manufacturer's labeling, and ExaVeyra Sciences makes no claim about clinical outcomes. Compounded medications are not FDA-approved finished drug products; they are prepared under section 503A against a prescription for an individual patient, dispensed by the pharmacy, and are prescription products rather than topical aesthetic products.

This page is provided for informational purposes only. It is not medical advice, it is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for the judgment of a licensed practitioner. Consult a healthcare professional before acting on anything stated here. Leer el aviso completo

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Leer el aviso completo